ClinicalTrials.gg
CompletedNCT01919944Updated Jun 3, 2015

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

A Phase 1 interventional study of VLY-686 and Placebo in Pruritus, sponsored by Vanda Pharmaceuticals. Completed at 1 site in Switzerland. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-03.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Pruritus with a site in Switzerland — 3 open to participants now, 5 under way, none of them phase 3. Pruritus · Switzerland.

Enrollment
12th of 12
12 · median 72
Started
2013
the only one that year
Phase 1
Only one
of the 17
Registered
2nd of 17
by date
Lead sponsor
1 of 17
Vanda Pharmaceuticals

Among the 17 studies in Pruritus with a site in Switzerland, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 1, and was the 2nd registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

3 of the 17 studies in Pruritus with a site in Switzerland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pruritus with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this study is to test whether VLY-686 can prevent or reduce the itch and dermatological reaction observed after healthy volunteers are injected with Substance P in comparison with placebo.

Read the detailed description

This is a double-blind, randomized, 4-way crossover, pharmacokinetic and pharmacodynamic (PK/PD) study to compare the cutaneous vasoreactive intensity to intradermal injections of Substance P in healthy volunteers receiving oral doses of 20 mg, 50 mg or 100 mg VLY-686 or a matching placebo. Twelve healthy male subjects satisfying the selection criteria for the study will be enrolled. Each subject will participate in a screening period (up to 21 days prior to dosing), four one-day treatment periods each separated by a 7 (±2 days) day washout period, and an end-of-study evaluation prior to discharge from the study. This protocol also includes an option of subjects administered daily doses of study medication between Periods 3 and 4. The treatment periods will be in a randomized sequence consisting of 1) 20 mg VLY-686, 2) 50 mg VLY-686, 100 mg VLY-686 and 4) placebo. In each of the study periods, Substance P will be injected 5 times: pre-dose (the night before), 2, 4, 8 and 12 hours (± 10 minutes) after study medication administration. A dose of 100 μL of a 2.5 nmol/mL sterile solution of Substance P will be injected each time. Overall, subjects will be administered 1.25 nmol of Substance P in around 24 hours (5 doses). Substance P injections will be given in the volar of the forearm, alternating right and left and avoiding injections in an area adjacent to the area previously injected. The subject's forearm will be covered during and after each injection to avoid potential biases in the scoring of the Verbal Rating Scale (VRS) and Visual Analog Scale (VAS). Additionally, blood samples for VLY-686 pharmacokinetic (PK) analysis will be collected each period at pre-dose, 1, 3, 6, 10, and 24 hours after study medication administration.

03

Conditions studied

  • Pruritus

Browse trials for

Keywords

  • itch
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males 18 - 45 years of age, inclusive;
  • Non-smokers, per medical history, or ex-smokers for a period of ≥1 year;
  • Subjects with (BMI) of ≥18.5 and ≤30 kg/m2 (BMI = weight (kg)/ [height (m)]2);
  • Vital signs (in sitting position after 3 minutes of rest) which are within the ranges shown below (inclusive):
  • Body temperature between 35.4-37.8 °C;
  • Systolic blood pressure between 91-130 mmHg;
  • Diastolic blood pressure between 51-90 mmHg;
  • Pulse rate between 50-100 bpm;
  • Respiratory rate between 10-20 breaths per minute;
  • Ability and acceptance to provide written ;
  • Willing and able to comply with study requirements and restrictions;
  • Subjects must be in good health as determined by past medical history, physical examination, , clinical laboratory tests and urinalysis.

Exclusion criteria

Exclusion Criteria:

  • Past or present history of atopy (atopic dermatitis problems, urticaria, asthma or allergic rhinitis) with no ascertained intolerance to histamine;
  • Past or present skin disease;
  • Lesions or any skin changes in the forearms in the month prior to the Screening Visit;
  • History of neurological diseases;
  • Past or present pain-related diseases such as cluster headaches, migraine, or back pain;
  • Treatment with all topical cream and ointments including cosmetics applied on the forearm in the 10 days prior to the screening visit;
  • Participation in the evaluation of any product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study;
  • Exposure (within 2 weeks of the Baseline Visit) to any prescription medication or over-the-counter medication including dietary supplements and/or herbal remedies, except those listed on Section 8.2;
  • Exposure (within 4 weeks of the Screening Visit) to any antihistamines, anxiolytics, antidepressants, pain killers including triptanes, neuroleptics, or sleep medications;
  • Treatment with any medication known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 days preceding the Screening Visit;
  • Administration of medications containing or adrenocorticotropic hormone in the three months prior to the Screening Visit;
  • reading considered outside the normal limits by the investigator (e.g. abnormally prolonged corrected by Fridericia's method > 450 msec in males, on ECG tracing). The following conduction abnormalities may confound QTc analysis and should be avoided if possible: PR > 220 msec, 2nd or 3rd degree AV block, intraventricular conduction delay with QRS > 120 msec, left branch bundle block, right branch bundle block or Wolff-Parkinson-White syndrome;
  • Blood donation in the last 3 months or donation of at least 1500 mL blood (including this study) within the last year;
  • History of liver disease and/or positive for one or more of the following serological results:
  • A positive antibody test (anti-HCV);
  • A positive surface antigen (HBsAg);
  • A positive test result ;
  • Not willing to sign the or not able to understand completely the study objectives or risks;
  • abnormalities in clinical lab or physical assessments performed at the screening visit;
  • Lack of sensitivity to Substance P and histamine or sensitivity to saline at the Screening Visit;
  • Any other sound medical reason as determined by the clinical Investigator.
  • Drug, alcohol, caffeine, tobacco: history of drug, alcohol (>2 drinks/day for males, defined according to USDA Dietary Guidelines 2010), caffeine (>5 cups coffee/tea/day), smokers;
  • Diet: abnormal diets (\<1600 or >3500 calories/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    VLY-686 20 mg

    Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules

    Drug: VLY-686

  • Experimental
    VLY-686 50 mg

    Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule

    Drug: VLY-686 · Drug: Placebo

  • Experimental
    VLY-686 100 mg

    Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules

    Drug: VLY-686

  • Placebo comparator
    Placebo

    Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules

    Drug: Placebo

Interventions

  • capsules containing either 10 mg or 50 mg VLY-686

  • DrugPlacebo

    Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule

06

What researchers measure

Primary outcomes

  1. Itch severity score on the Verbal Rating Scale

    Time frame: 20 minutes after Substance P injection

  2. Itch severity score on the Visual Analog Scale

    Time frame: 20 minutes after Substance P injection

Secondary outcomes

  1. Dose response of VLY-686 and reduction of itch severity

    Time frame: 20 minutes after substance P injection

  2. Number of adverse events in subjects taking VLY-686

    Time frame: 24 hours after Substance P injection

  3. Size of injection site erythema

    Time frame: 1-20 minutes after Substance P injection

  4. Number of adverse events in subjects taking placebo

    Time frame: 20 minutes after Substance P inection

  5. Size of injection site and urticaria

    Time frame: 20 minutes after Substance P injection

07

Study locations

1 site
  • Vanda Investigational Site
    Arzo, CH 6864, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2013
First posted
Aug 9, 2013
Start
Aug 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Jun 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01919944
Responsible party
Sponsor
First posted
Aug 9, 2013
Start date
Aug 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Jun 3, 2015

Study contacts

Milko Radicioni, MD
principal investigator · Cross Research SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion